gross profit bridgeinconsistent2025-03-31
Withheld: gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$364.25M
Fiscal year ended 2026-06-30Operating income
-$56.31M
Fiscal year ended 2026-06-30Free cash flow
$19.08M
Fiscal year ended 2026-06-30MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $364.25M and net income of -$57.94M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from MADRIGAL PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | $137.25M | $103.32M | $62.18M | $14.64M | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $4.51M | Unavailable | Unavailable | Unavailable | $0 |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $0 |
| Operating income | -$56.31M | -$92.72M | -$59.61M | -$113.98M | -$47.20M | -$79.31M | -$67.00M | -$116.30M | -$162.54M | -$152.04M |
| Net income | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | -$73.24M | -$59.42M | -$106.96M | -$151.97M | -$147.54M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 29.15M | shares 29.03M | Unavailable | shares 28.51M | shares 28.23M | shares 28.09M | Unavailable | shares 21.75M | shares 21.40M | shares 20.00M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-1.99 | $-3.25 | Unavailable | $-4.01 | $-1.50 | $-2.61 | Unavailable | $-4.92 | $-7.10 | $-7.38 |
| Selling, general & administrative | $289.38M | $268.52M | $239.98M | $209.12M | $196.86M | $167.88M | $141.22M | $107.58M | $105.45M | $80.80M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $292.73M | $227.03M | $198.69M | $295.69M | $186.19M | $183.65M | $100.02M | $232.68M | $494.60M | $622.52M |
| Total assets | $1.24B | $1.23B | $1.26B | $1.36B | $1.02B | $996.63M | $1.04B | $1.07B | $1.10B | $1.08B |
| Current assets | $1.20B | $1.18B | $1.25B | $1.35B | $1.00B | $987.98M | $1.03B | $1.06B | $1.09B | $1.07B |
| Total liabilities | $720.92M | $683.87M | $656.90M | $736.72M | $319.40M | $285.99M | $287.86M | $296.11M | $242.67M | $231.52M |
| Current liabilities | $374.20M | $338.26M | $310.29M | $391.41M | $196.50M | $167.24M | $169.28M | $177.85M | $125.16M | $114.34M |
| Total equity incl. NCI | $523.72M | $543.45M | $602.69M | $625.73M | $695.98M | $710.64M | $754.38M | $777.16M | $857.12M | $850.76M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $99.39M | $112.07M | $74.84M | $69.32M | $63.50M | $55.24M | $34.07M | $8.72M | $7.07M | $854.00K |
| Accounts receivable | $192.31M | $187.36M | $134.48M | $113.28M | $79.23M | $61.43M | $53.82M | $30.46M | $6.90M | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | $340.79M | $340.33M | $339.88M | $339.75M | $118.38M | $118.00M | $117.57M | $117.09M | $116.61M | $116.14M |
| Accounts payable | $34.51M | $60.80M | $48.88M | $44.94M | $37.98M | $42.06M | $43.60M | $45.97M | $8.99M | $21.53M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.33M | -$167.44M | -$133.46M | $79.85M | -$47.05M | -$88.89M | -$104.49M | -$66.98M | -$134.94M | -$149.16M |
| Capital expenditures | $4.25M | $3.85M | -$390.00K | $857.00K | $0 | $0 | $195.00K | $779.00K | $131.00K | $357.00K |
| Investing cash flow | $34.20M | $192.19M | $27.58M | -$207.00M | $47.86M | $163.88M | -$47.95M | -$202.39M | -$122.10M | $98.05M |
| Financing cash flow | $3.11M | $2.33M | $8.96M | $236.65M | $1.74M | $8.64M | $19.77M | $7.46M | $134.12M | $573.71M |
| Net change in cash | $60.69M | $28.40M | -$96.91M | $109.50M | $2.55M | $83.63M | -$132.66M | -$261.91M | -$122.92M | $522.60M |
| Stock-based compensation | $35.37M | $34.02M | $25.79M | $26.25M | $25.16M | $20.93M | $17.68M | $17.90M | $24.40M | $19.90M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $381.00K | $386.00K | $392.00K | $358.00K | $377.00K | $379.00K | $363.00K | $298.00K | $267.00K | $168.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $19.08M | -$171.28M | Unavailable | $78.99M | -$47.05M | -$88.89M | -$104.68M | -$67.76M | -$135.08M | -$149.51M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | -15.5% | -29.8% | -18.6% | -39.7% | -22.2% | -57.8% | -64.8% | -187.1% | -1110.4% | Unavailable |
| FCF margin | 5.2% | -55.0% | Unavailable | 27.5% | -22.1% | -64.8% | -101.3% | -109.0% | -922.8% | Unavailable |
| SBC / revenue | 9.7% | 10.9% | 8.0% | 9.1% | 11.8% | 15.3% | 17.1% | 28.8% | 166.7% | Unavailable |
| Current ratio | 3.20x | 3.50x | 4.01x | 3.44x | 5.11x | 5.91x | 6.10x | 5.98x | 8.72x | 9.39x |
| Revenue YoY growth | 71.2% | 126.8% | 210.8% | 362.0% | 1353.8% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net margin | -15.9% | Unavailable | -18.2% | -39.8% | -19.9% | Unavailable | -57.5% | -172.0% | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 1.2% | 1.2% | -0.1% | 0.3% | 0.0% | 0.0% | 0.2% | 1.3% | 0.9% | Unavailable |
| Long-term debt / equity | 0.65x | Unavailable | 0.56x | 0.54x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MDGL in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.